Biotech Startups

Daxiang Bio develops organ-on-chip systems that recreate organ physiology and pathology in vitro to enable drug response prediction and medical research. The technology is applied in pharmaceutical development and biomedical research.

1 investor

Daya CNS is a pharmaceutical company focused on drug discovery and development for central nervous system disorders, with expertise in small molecule therapeutics targeting pain and related conditions.

1 investor

Duoseq offers a comprehensive cancer genomics assay that profiles both DNA and RNA from a single sample in one preparation, delivering mutations, expression, fusions, and clonotype data with sample-to-report turnaround in about two days. It is built for on-site lab use with robotic workflow automation and integrates directly with EPIC and other EHR systems.

1 investor

De Novo Dairy produces nature-identical bovine lactoferrin using precision fermentation instead of dairy extraction, offering customizable iron-saturation profiles, purity, and sequence identity per batch. It targets product formulators across categories such as infant formula, gut-health supplements, and bioavailable iron delivery.

1 investor

DealForma provides a data platform and analyst support for biopharma business development teams to research partnerships, deals, funding trends, and therapeutic areas. The service combines curated company profiles from thousands of industry sources with direct analyst assistance for deal preparation and strategic research.

1 investor

Regeneron is a biopharmaceutical company that discovers, develops, and commercializes medicines using proprietary technologies and genetic databases. The company serves patients with serious diseases across oncology, immunology, ophthalmology, and other therapeutic areas.

1 investor

Deciphera is a pharmaceutical company focused on developing treatments for people living with cancer. Its work centers on oncology drug development and support for patient communities.

1 investor

DecisionRx is a health technology company focused on medication decision support and pharmacy operations within the diagnostics and pharmacogenomics space. Its leadership brings experience from diagnostics labs, health insurers, and healthcare technology firms.

1 investor

DeckTherapeutics is a biotech company developing acute omega-3 therapeutics, with a lead neuroprotectant candidate (THDG3) aimed at hypoxic-ischemic brain injuries such as neonatal hypoxic-ischemic encephalopathy and ischemic stroke. The company seeks partners to advance its omega-3 platform and intellectual property.

1 investor

Decode Love is a pilot program that analyzes a participant's DNA (SNPs) alongside a psychology survey to produce a personalized report scoring five clusters of emotional and personality traits. It positions this as a self-discovery and relationship self-awareness tool for individuals, framed around genetics and psychology rather than dating or matchmaking.

1 investor

Decoy Smart develops biological pest control solutions for animal health and agriculture, targeting parasites such as ticks and fleas in cattle, horses and pets, beetles in poultry farms, and the Varroa mite affecting bees. The company applies science-based biological methods as alternatives for controlling pests in livestock and farming environments.

1 investor

Deep Origin develops a physics-based simulation platform for drug discovery that models biological systems across scales from quantum to cellular level with explainable physics rather than black-box AI. It serves pharmaceutical and biotech researchers, including work under an ARPA-H program aimed at replacing animal testing.

1 investor

Deepflare provides an AI platform for antigen design that predicts T-cell immunogenicity to accelerate vaccine and therapeutic discovery. The platform serves biotech companies and researchers developing viral and cancer treatments.

1 investor

Deep MedChem develops CHEESE, a family of AI products for drug discovery that let researchers search, predict, and explore 2D, 3D shape, electrostatic, and activity similarity across 40T+ molecules, deployable on cloud or on-premises. It serves pharmaceutical and biotech drug discovery teams and is a spin-off from The MAMA AI and i&i Prague connected to the IOCB medicinal chemistry institute in Europe.

1 investor

Deffai is an AI-native regulatory affairs platform that helps life sciences companies prepare and strengthen FDA submissions using domain-specific AI built on review patterns and guidances. It targets biotech and medical device firms working on areas such as cell and gene therapy, vaccines, oncology, and combination products, and is staffed by former FDA reviewers and decision-makers.

1 investor

Defined Bioscience develops cell culture media, growth factors, and related reagents for stem cell biology and regenerative medicine research. The company supplies branded products for laboratory and research use.

1 investor

Definigen manufactures iPSC-derived human hepatocytes for drug discovery and disease modeling. The product line supports preclinical toxicity testing, metabolism studies, and disease research in pharmaceutical development.

1 investor

Isolates and analyzes circulating tumor cells from blood for early-stage cancer detection.

1 investor

Deliver Biosciences develops a nanoparticle-based delivery platform to genetically engineer cells in patients for cell and gene therapies, targeting cancer immunotherapies as the first indication with applications in autoimmune, neurodegenerative, and cardiovascular diseases.

1 investor

DELiver Therapeutics develops small molecule and peptide therapeutics using high-throughput DNA encoded library (DEL) drug screening to address challenging and previously "undruggable" targets in clinical medicine, with a focus on tyrosine kinase targets. Its R&D facilities are located at K2Bio in Houston.

1 investor

Deliver Biosciences develops a nanoparticle-based delivery platform to genetically engineer cells inside patients (in vivo) for cell and gene therapies, using programmable targeting to transport payloads such as DNA and mRNA to specific cell types. Its first product targets T-cells to deliver a CAR gene for cancer immunotherapy, with longer-term applications in autoimmune, neurodegenerative, and cardiovascular diseases.

1 investor

DelNova is a life science company developing proprietary assets in medical aesthetics and neuromuscular therapeutics, having advanced from early research into Series A financing. Its work relates to injectable aesthetics such as neurotoxins and peripheral nerve applications.

1 investor

Delox develops proprietary bio-decontamination solutions using solid-formulated hydrogen peroxide technology for healthcare, pharmaceutical, laboratory, and industrial environments where contamination control is critical. The company operates across Europe and North America, serving organizations in highly controlled settings that require precision decontamination with zero tolerance for failure.

1 investor

Delpharm is a contract development and manufacturing organization (CDMO) that develops and manufactures pharmaceutical products for the pharmaceutical industry across solid, sterile, semi-solid, and liquid dosage forms. With manufacturing sites across Europe and North America, the company ranks among the top 5 global CDMOs and specializes in pre-filled syringes, nasal sprays, and liquid pharmaceuticals.

1 investor